Tirzepatide matched dulaglutide for major cardiovascular events but did not prove superior cardiovascular protection in SURPASS-CVOT.
Evidence
This commentary highlights SURPASS-CVOT, an active-comparator cardiovascular outcomes trial in type 2 diabetes where tirzepatide was noninferior to dulaglutide for (HR 0.92; 95.3% CI 0.83-1.01; p = 0.086) despite greater HbA1c and weight reductions.
Caveat
Superiority over dulaglutide was narrowly missed, and exploratory mortality, renal, and imputed-placebo findings require cautious interpretation.
Simplified
Despite advances in cardiovascular risk reduction in type 2 diabetes (T2D), a persistent gap remains compared to individuals without diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1RA) have provided consistent cardiovascular benefits. With more cardiovascular protective agents available for diabetes management, their incremental effect may be nearing a ceiling. The SURPASS-CVOT trial innovatively compared the dual GIP/GLP-1RA tirzepatide with the selective GLP-1RA dulaglutide, demonstrating noninferiority for major adverse cardiovascular events (; HR 0.92; 95.3% CI 0.83-1.01; p = 0.086) and suggesting a potential 28% MACE risk reduction versus an imputed placebo. However, superiority over dulaglutide was narrowly missed. Despite greater improvements in glycemia (0.8% greater HbA1c reduction) and weight (7% greater weight loss), tirzepatide appeared to confer limited incremental cardiovascular benefit, raising questions about mechanism saturation or trial design constraints. Exploratory analyses showed promising benefits on mortality and renal function but require cautious interpretation. The trial's active comparator/imputed placebo design reflects an evolving ethical and therapeutic landscape in diabetes care. Whether dual incretin receptor agonism can meaningfully exceed current cardioprotective thresholds remains uncertain. By now, we may need new paradigms to overcome what may turn out to be a therapeutic ceiling for cardiovascular protection in the T2D population.
Key numbers
28%
Risk Reduction
Risk reduction in from tirzepatide.
0.8%
HbA1c Reduction
Tirzepatide's HbA1c reduction compared to dulaglutide.
7%
Weight Loss
Weight loss achieved with tirzepatide compared to dulaglutide.
Full Text
We can’t show the full text here under this license.
Declarations. Conflict of Interest: Gian Paolo Fadini received honoraria, consultancy or lecture fees from AstraZeneca, Boehringer, Guidotti, Lilly, Novartis, and Sanofi. GPF is an Editorial Board member of Diabetes Therapy. GPF was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Ethical Approval: No ethical approval was sought as this article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by the author.
